Velasof Tablet

Velasof Tablet

Prescription requiredRx Required

Salt Composition: Sofosbuvir and Velpatasvir

Expiry Date: 01/2028

Special offer

Enquire

Inclusive of all taxes

▼

28 tablet

About The Product

Chronic hepatitis C virus (HCV) infection

Velasof Tablet is a viral treatment medication that is used for treating chronic hepatitis C virus infections. This tablet is comprised of two constituents that are sofobuvir and velpatasvir of strength 400mg and 100mg respectively. It helps protect the liver, reduces the risk of cirrhosis and liver cancer, and can cure more than 95 percent of patients. The usual length of treatment is 12 weeks. One tablet is taken each day, with or without food. Side effects can include headache, tiredness, nausea, and sleep problems. Patients should avoid alcohol and tell their doctor about any other health problems or medications they are taking, especially if they have kidney or severe liver problems.

Overview

The formation of Velasof Tablets is made up of both Sofosbuvir (400 mg) and Velpatasvir (100 mg). This pair works unitedly in healing chronic hepatitis C infections.

They function to stop viral reproduction in the body and help to clear the virus from the body naturally. As per the doctor's advice, this medicine is consumed once daily.

Common side effects of Velasof Tablets include headache, tiredness, nausea, and weakness.

Quick Product Facts

Item

Detail

Generic name

Sofosbuvir and velpatasvir fixed-dose combination

Strength

Sofosbuvir 400 mg and velpatasvir 100 mg in each tablet

Maker and approval

Hetero. DCGI approval was announced on 5 May 2017. Reference product: Gilead's Epclusa

Pack

28 tablets

Drug class

NS5B nucleotide polymerase inhibitor plus NS5A inhibitor

Usual dose

One tablet once daily, with or without food

Boxed warning

Risk of hepatitis B virus reactivation in people infected with both viruses

Storage

Keep at room temperature (20°C to 25°C / below 25°C). Do not freeze.

Prescription status

Prescription medicine.

Price control

The price of the Velasof tablet is not fixed; it varies depending on the location, availability, and manufacturing.

Price

The price of the tablet is not constant; it varies depending upon the pharmacy, location, and manufacturing.

Velasof Tablet Uses and Indications

The uses of the Velasof tablet are several. It is used for the treatment of chronic hepatitis C of genotypes 1, 2, 3, 4, 5, or 6. It covers adults and children aged 3 and older. This includes people:

  • Without cirrhosis or with compensated cirrhosis (Child-Pugh A), taking the tablets alone;

  • With decompensated cirrhosis (Child-Pugh B or C), taking the tablets together with ribavirin.

Velasof tablet does not treat hepatitis B, HIV, or liver cancer. Velasof 400/100 mg suits only adults and children who weigh at least 30 kg.

How Velasof Tablet Works

Sofosbuvir present in the Velasof tablet is a prodrug. The body turns it into an active form that is built into the virus's genetic material and stops the copying enzyme, NS5B, from working. Velpatasvir present in Velasof tablet blocks a second viral protein, NS5A, that the virus needs to multiply. Together they stop the virus from replicating across all six genotypes.

Sofosbuvir 400mg reaches its peak within 0.5 to 1 hour, and velpatasvir 100mg at about 3 hours. The main breakdown of sofosbuvir has a half-life of about 25 hours, and velpatasvir about 15 hours, so one tablet a day is enough. Meals raise exposure somewhat, but the velasof tablet can be taken with or without food.

Clinical Evidence for Velasof Tablet

12 weeks of the combination cleared the virus in about 95% to 99% of people in the main trials. The lowest rates were in genotype 3 with cirrhosis and in decompensated cirrhosis.

Study

Setting

Result (no virus 12 weeks after treatment)

ASTRAL-1

624 adults with genotypes 1, 2, 4, 5, or 6, 12 weeks, vs placebo

99% overall. Genotype 1a 98%, 1b 99%, 2 100%, 4 100%, 5 97%, 6 100%. No placebo patient was cured.

ASTRAL-2

Genotype 2: 134 on the combination vs 132 on sofosbuvir plus ribavirin

99% vs 94%.

ASTRAL-3

Genotype 3: 277 on the combination for 12 weeks vs 275 on sofosbuvir plus ribavirin for 24 weeks

95% vs 80%. With compensated cirrhosis: 93% if new to treatment, 89% if treated before.

ASTRAL-4

87 people with decompensated cirrhosis, combination plus ribavirin, 12 weeks

94% overall. Genotype 1: 96%. Genotype 3: 85%.

ASTRAL-5

106 people with hepatitis C and HIV

95%.

Other groups

Liver transplant (79); dialysis (59); people who inject drugs (103); children 12 to 17 (102)

96%; 95%; 94%; 93% in genotype 1 and 100% in genotypes 2, 3, 4, and 6.

Genotype 3 with cirrhosis and the NS5A variant Y93H is the hardest case: 6 of 15 such people (40%) had treatment failure. The efficacy is not established in people who failed earlier treatment that included an NS5A inhibitor.

Velasof Tablet Side Effects

Most people have mild effects. In ASTRAL-1, 0.2% stopped treatment because of side effects, and many effects were as common on placebo as on treatment.

Effect

12 weeks alone (ASTRAL-1)

With ribavirin, decompensated (ASTRAL-4)

Headache

22%

11%

Fatigue

15%

32%

Nausea

9%

15%

Insomnia

5%

11%

 

With ribavirin, hemoglobin fell below 10 g/dL in 23% of people and below 8.5 g/dL in 7%, and 17% had to stop ribavirin. Rash occurred in 2% on the combination alone and 5% with ribavirin.

Serious side effects

Serious effects are rare, but each needs quick action.

  • Hepatitis B reactivation: in people carrying hepatitis B as well, treatment can wake the virus. Some cases caused fulminant hepatitis, liver failure, and death.

  • Slow heartbeat with amiodarone: serious symptomatic bradycardia, some needing a pacemaker, and one fatal cardiac arrest, reported with sofosbuvir regimens.

  • Skin and swelling: skin rashes, sometimes with blisters, and angioedema were reported after approval.

  • Blood sugar and clotting tests: as the liver recovers, diabetic patients had serious low blood sugar, and INR can change in people on warfarin.

  • Lab changes: isolated lipase rises above 3 times normal in 3% to 6%, and creatine kinase rises in 1% to 2%, without symptoms.

Critical Safety Warning

Call your local emergency number now for:

  • Fainting or near-fainting, a very slow heartbeat, chest pain, or shortness of breath, especially if you took or recently took amiodarone.

  • Swelling of the face, lips, tongue, or throat, or trouble breathing.

  • Yellow eyes or skin with confusion, severe drowsiness, vomiting blood, or a swollen belly (possible liver failure).

Call your doctor the same day for:

  • Dark urine, pale stools, new yellow eyes or skin, or severe tiredness with nausea and vomiting (possible hepatitis B reactivation).

  • A widespread rash, blisters, or swelling.

  • Shakiness, sweating, hunger, confusion, or fainting if you have diabetes (low blood sugar).

  • Dizziness, light-headedness, or unusual weakness if you take heart medicines.

  • If you take ribavirin: You may experience breathlessness, a racing heart, or looking very pale (anemia).

The boxed warning says to test everyone for current or past hepatitis B (HBsAg and anti-HBc) before starting. Reactivation can occur even in people who have cleared it. The only contraindication is that the combination with ribavirin cannot be used where ribavirin is contraindicated, which includes pregnancy and men whose partners are pregnant.

Velasof Tablet Dosage and How To Take It

One velasof tablet once a day for 12 weeks, with or without food. People with decompensated cirrhosis also take ribavirin.

Who

Regimen

Adults with no cirrhosis or compensated cirrhosis (Child-Pugh A)

One tablet (400 mg + 100 mg) once daily for 12 weeks

Adults, decompensated cirrhosis (Child-Pugh B or C)

One tablet once daily plus ribavirin for 12 weeks

Liver transplant, no cirrhosis or compensated cirrhosis

One tablet once daily for 12 weeks

Hepatitis C with HIV

One tablet once daily for 12 weeks; antiretroviral interactions must be checked.

Kidney problems, including dialysis

No dose change

Children 3 and older

Weight-based: under 17 kg, 150/37.5 mg pellets; 17 to under 30 kg, 200/50 mg; 30 kg or more, 400/100 mg tablet

  • Ribavirin: 1,000 mg a day if under 75 kg and 1,200 mg if 75 kg or more, split into two doses and taken with food. The dose is lowered by hemoglobin and kidney function.

  • Before the first tablet: test for hepatitis B (HBsAg and anti-HBc).

  • Acid-lowering medicines: separate antacids by 4 hours. Famotidine-type tablets can be taken together or 12 hours apart, up to a dose of famotidine 40 mg twice daily. Omeprazole and other proton-pump inhibitors are not recommended.

  • Length of treatment: 12 weeks. Do not stop early, even if you feel well.

  • Food and drink: the tablet can be taken with or without food.

For pharmacists and prescribers

  • Dispensing check: confirm hepatitis B status is recorded, then check for amiodarone, rifampicin, anticonvulsants, St. John's wort, efavirenz, acid-lowering medicines, statins, and warfarin.

  • Amiodarone: if no alternative exists, the label advises inpatient cardiac monitoring for the first 48 hours, then daily pulse checks every at least 2 weeks.

Velasof Tablet Missed Dose

  • Call your doctor or pharmacist for advice, and do not take two tablets to catch up.
  • In the trials, one treatment failure was consistent with missed doses, so tell your doctor if you miss tablets.

Safety Advice for Velasof Tablet

Hepatitis B

Test before treatment and monitor during and after therapy.

Heart medicines

Avoid amiodarone unless no alternative; monitor heart function.

Pregnancy

Consult a doctor; the ribavirin combination is contraindicated during pregnancy.

Breastfeeding

Discuss potential risks and benefits with your doctor.

Diabetes and warfarin

Monitor blood glucose and INR regularly.

Kidney and liver problems

No dose adjustment is generally required; monitor liver function in decompensated cirrhosis.

Older adults

No dose adjustment is generally required.

People who inject drugs

No dose adjustment required; monitor for possible reinfection.

Monitoring During Velasof Treatment

Check

Guidance

Why

Hepatitis B tests (HBsAg, anti-HBc)

Before starting

Reactivation risk

Liver tests and hepatitis flare signs

During treatment and follow-up if hepatitis B is present

Reactivation

Heart rate if on amiodarone

Inpatient monitoring for 48 hours, then daily pulse for at least 2 weeks

Slow heartbeat

Blood sugar in diabetes

Frequent monitoring and dose changes as needed

Low sugar

INR on warfarin

Frequent monitoring

Clotting changes

Hemoglobin and kidney function with ribavirin

Adjust ribavirin by results.

Anemia

Liver tests with direct bilirubin in decompensated cirrhosis

As clinically indicated

Safety in advanced disease

HCV RNA 12 weeks after the last tablet

The trials' cure test (SVR12)

Confirm cure

Velasof Tablet Fact Box

Item

Detail

Molecules

Sofosbuvir, molecular weight 529.45; velpatasvir, 883.0

Protein binding

Sofosbuvir 61% to 65%; velpatasvir above 99.5%

Elimination

Sofosbuvir mainly as its metabolite in urine (about 80%); velpatasvir mainly in feces (about 94%)

Heart rhythm (QT)

No clinically relevant QT prolongation at 3 times (sofosbuvir) and 5 times (velpatasvir) of the dose

Boxed warning

Hepatitis B reactivation

Contraindication

Combination with ribavirin where ribavirin is contraindicated

Overdose

No antidote. Support and monitoring. Dialysis removes the main sofosbuvir metabolite but not velpatasvir.

Resistance

Not established after failure of regimens that include an NS5A inhibitor

Velasof Tablet Drug Interactions

Tell your team about every medicine and herbal product you take.

Drug / Class

Potential Interaction or Risk

What To Do

Rifampicin, rifabutin, rifapentine

Reduced antiviral effectiveness

Avoid combination.

Carbamazepine, phenytoin, phenobarbital

Reduced medicine levels

Avoid combination.

St. John's wort

Reduced antiviral effectiveness

Avoid use.

Efavirenz, tipranavir/ritonavir

Significant drug interactions

Avoid combinations.

Amiodarone

Risk of serious slow heart rate

Avoid combinations.

Antacids

Reduced drug absorption

Separate by 4 hours

Famotidine and PPIs

May reduce velpatasvir absorption

Follow recommended dosing.

Rosuvastatin, atorvastatin

Increased risk of muscle damage

Monitor for muscle symptoms.

Digoxin

Increased digoxin levels

Monitor blood levels.

Tenofovir DF

Increased kidney-related risks

Monitor kidney function.

Warfarin

Changes in INR

Monitor INR

Diabetes medicines

Risk of low blood sugar

Monitor glucose levels.

Other listed medicines (methadone, dolutegravir, cyclosporine, and oral contraceptives)

No significant interaction generally expected

Routine monitoring

FAQs About Velasof Tablet

Velasof tablet treats chronic hepatitis C caused by genotypes 1 to 6 in adults, with or without compensated cirrhosis. People with decompensated cirrhosis take it with ribavirin.

It does not treat hepatitis B, HIV, or liver cancer. Your doctor confirms your genotype and liver status before choosing the regimen.

References

  1. Gilead Sciences. EPCLUSA (sofosbuvir and velpatasvir) tablets and oral pellets, US prescribing information, revised 04/2022.

  2. Hetero. Hetero receives DCGI approval for generic sofosbuvir and velpatasvir (Velasof), press release, 5 May 2017.

  3. Daily Excelsior. Hetero gets DCGI nod for generic chronic hepatitis C drug, 5 May 2017.

  4. myUpchar. Velasof tablet listing, Hetero Drugs Ltd, strip of 28.

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026